Pro-PEG3-BA
Pro-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader, degrading EML4 ALK and EGFR mutant (L858R/T790M) with DC50 values of 0.42 and 13.50 μM, respectively. Pro-PEG3-BA hinders proliferation and induces cell cycle arrest and apoptosis of NSCLC cells in vitro. Pro-PEG3-BA shows safety profile and decreases EML4-ALK protein via rewiring the ubiquitin- proteasome system in vivo. Pro-PEG3-BA can be used for non-small cell lung cancer research.
(Pink: EGFR and EML4-ALK ligand (HY-150908); Blue: Ligands for E3 Ligase ligand (HY-Y0252); Black: linker (HY-W040165)).
For research use only. We do not sell to patients.
- CAS No.: 3057939-64-4
- Formula: C37H52ClN8O7P
- Molecular Weight:787.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H1975 | IC50 |
8.8 μM
Compound: Pro-PEG3-BA
|
Inhibition of cell viability in human NCI-H1975 cells incubated for 48 to 72 hrs by CCK8 assay
Inhibition of cell viability in human NCI-H1975 cells incubated for 48 to 72 hrs by CCK8 assay
|
[PMID: 39114932] |
In Vitro
Pro-PEG3-BA (0-50 min) binds to purified ALK with a Kd of 387 nM in vitro [2]. Pro-PEG3-BA binds GID4 protein with Kd value of 6.05 μM in HEK293T cells[3].
Pro-PEG3-BA (0-20 μM, 48 h) specifically degradest EML4 ALK fusion in H3122 (EML4-ALK), with no effect on wild type or mutant ALK[3].
Pro-PEG3-BA (48-72 h) inhibits H3122 cells (48 h) prolifetion with an IC50 value of 0.16 μM, inhibits H1975 cells (EGFR-L858R/T790M) (72 h) prolifetion with an IC50 value of 8.80 μM[3].
Pro-PEG3-BA (48-72 h) inhibits cell growth with an IC50 value of 0.16 μM for H3122 (EML4-ALK) cells (48 h), and 8.8 μM for H1975 (EGFR-L858R/T790M) (72 h) cells, with little toxicity to normal cells (HEK293T cells)[3].
Pro-PEG3-BA (10 μM, 24 h) dramatically downregulates ALK protein abundance alongside CD2AP, MRPS23, RNF2, RAB18 and TRMT10C, demonstrating high selectivity in targeting ALK for degradation; concurrently, it upregulates POLR2F, WASHC2C, NCOR2, ZNF622, ALDH6A1, PRRC1, GPD1L, EXOC7, WACPAF1 in H1975 (EGFR L858R/T790M) cells[3].
Pro-PEG3-BA (10-20 μM, 0-24 h) induces the apparent reduction of EML4-ALK or EGFR mutant proteins in a time-dependent manner in H3122 (EML4-ALK) cells (10 μM) and H1975 (EGFR-L858R/T790M) cells (20 μM)[3].
Pro-PEG3-BA (0.5-20 μM, 6 or 12 h) reduces the levels of EML4-ALK and EGFR mutants in a proteasome-dependent manner in H3122 (EML4-ALK) and H1975 (EGFR-L858R/T790M) cells[3].
Pro-PEG3-BA (5-10 μM, 48-72 h) induces cell cycle arrest and apoptosis in H1975 (EGFR-L858R/T790M) cells and H3122 (EML4-ALK) cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H3122 cells (EML4-ALK), SK-N-BE(2) (express wild type ALK, and SH-SY5Y) and SH-SY5Y (harbors the ALK-F1174L)
-
Concentration:0, 0.01, 0.1, 1, 10 and 20 μM
-
Incubation Time:48 h
-
Result:Led to a noticeable downregulation of the EML4-ALK protein in H3122 (EML4-ALK) cells.
Did not affect the protein levels of either wild-type or mutant ALK.
-
Cell Line:H3122 cells (EML4-ALK) and H1975 (EGFR L858R/T790M) cells
-
Concentration:0.5 or 20 μM
-
Incubation Time:6 h and 12 h
-
Result:Mediated the degradation of EML4-ALK or EGFR mutant, which was blocked by the proteasome inhibitor MG132 (HY-13259) (10 μM) instead of lysosome inhibitor Chloroquine (HY-17589A) (25 μM).
-
Cell Line:H3122 (10 μM) and H1975 (20 μM )
-
Concentration:H3122 (10 μM) and H1975 (20 μM)
-
Incubation Time:0, 12, 24, 36, 48 and 72 h
-
Result:Induced the apparent reduction of EML4-ALK or EGFR mutant proteins, with effects observed around 45 min and 12 h.
-
Cell Line:H3122 cells (EML4-ALK) and H1975 (EGFR L858R/T790M) cells
-
Concentration:5 or 10 μM
-
Incubation Time:48 (for H3122 cells) or 72 h (for H1975 cells)
-
Result:Induced an accumulation of cells in the G1 phase and concurrently causing a decrease in the number of cells in the S or G2 phase.
Significantly increased the proportion of both early and late apoptotic cells in a concentration-dependent manner.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H3122 cells induced-female nude mice[3]
-
Dosage:10 mg/kg
-
Administration:i.p., every other day for a total of 8 doses
-
Result:Did not cause significant variations in the mice body weight.
Decreased EML4-ALK protein levels in tumors.
Chemical Information
-
CAS No. 3057939-64-4
-
Molecular Weight 787.28
-
Formula C37H52ClN8O7P
-
SMILES
COC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)P(C)(C)=O)=N2)C=CC(N4CCN(CC4)C(CCOCCOCCOCCNC([C@@H]5CCCN5)=O)=O)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. Chen X, et al. Mighty mini-PROTACs: an emerging class of degraders. Eur J Med Chem. 2026 Jan 5;301:118202. [Content Brief]
[2]. Zhang J, et al. Linker-free PROTACs efficiently induce the degradation of oncoproteins. Nat Commun. 2025 May 23;16(1):4794. [Content Brief]
[3]. Zhang J, et al. Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC). J Med Chem. 2024 Aug 22;67(16):13666-13680. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)